Institutions selling this is eventually going to $5!
$7.16 pps values amrn at $1.09 billion. With no profits, a poor launch and massive dilution coming eoy as drug will take a few years to gain traction.
Big pharma probably never interested as not even a partnership was ever signed and a high interest loan secured with intellectual property. Add a looming reduce-it trial that could make or break all fish oils.
Sad part is it's the retailers who bought high rather then institutions who got in at under $2.00 who will be left holding bags.